Bristol Myers Squibb (NYSE: BMY) has announced positive top-line results from two studies on Breyanzi (lisocabtagene maraleucel), its CD19-directed CAR-T cell therapy.
The data is from TRANSCEND FL, a Phase II, single-arm study in relapsed or refractory follicular lymphoma (FL), and TRANSCEND NHL 001, a Phase I, single-arm study in relapsed or refractory B-cell non-Hodgkin lymphoma, including mantle cell lymphoma (MCL).
Results showed both studies met the primary endpoint of overall response rate, with Breyanzi demonstrating statistically significant and clinically meaningful responses in relapsed or refractory FL and MCL.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze